| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — | 190,2 k € | +1146.1% | 15,3 k € | -43.3% | 26,9 k € | -95.2% | 560,8 k € | +25.8% | 445,8 k € | -9.7% | 493,9 k € | |||||||||
| Gross margin | 288,4 k € | -35.1% | 444,6 k € | +5.9% | 419,7 k € | +15.5% | 363,4 k € | +81.7% | 200,0 k € | +93.2% | 103,6 k € | -8.0% | 112,6 k € | +16.1% | 96,9 k € | — | — | — | — | — | — | |||||||
| EBITDA | 19,4 k € | -37.9% | 31,3 k € | -14.7% | 36,6 k € | -10.0% | 40,7 k € | +128.9% | 17,8 k € | +502.0% | 3,0 k € | +2235.3% | 126,4 € | +103.6% | -3,5 k € | -153.2% | 6,5 k € | +1782.3% | 347,6 € | -89.7% | 3,4 k € | -90.4% | 35,2 k € | +18.8% | 29,6 k € | -11.7% | 33,6 k € | |
| Operating profit | 19,4 k € | -37.9% | 31,3 k € | -14.7% | 36,6 k € | -10.0% | 40,7 k € | +128.9% | 17,8 k € | +502.0% | 3,0 k € | +2235.3% | 126,4 € | +103.6% | -3,5 k € | -153.2% | 6,5 k € | +1782.3% | 347,6 € | -89.7% | 3,4 k € | -90.4% | 35,2 k € | +18.8% | 29,6 k € | -11.7% | 33,6 k € | |
| Profit/loss | 27,6 k € | +103.1% | 13,6 k € | -54.8% | 30,1 k € | -2.0% | 30,7 k € | +244.3% | 8,9 k € | +1250.7% | 659,6 € | +125.1% | -2,6 k € | +48.8% | -5,1 k € | -372.6% | 1,9 k € | — | 2,6 k € | -88.6% | 22,4 k € | +20.4% | 18,6 k € | -19.5% | 23,1 k € | |||
| Equity | 181,0 k € | +18.0% | 153,4 k € | +9.7% | 139,8 k € | +27.4% | 109,8 k € | +38.8% | 79,1 k € | +12.7% | 70,2 k € | -3.7% | 72,9 k € | -3.5% | 75,5 k € | -6.4% | 80,6 k € | +2.4% | 78,8 k € | 0.0% | 78,8 k € | +3.4% | 76,2 k € | +41.7% | 53,8 k € | +53.0% | 35,1 k € | |
| Total assets | 365,4 k € | +29.8% | 281,4 k € | -5.5% | 297,9 k € | +39.3% | 213,9 k € | +60.1% | 133,6 k € | +16.3% | 114,9 k € | -11.4% | 129,6 k € | +18.5% | 109,4 k € | -7.0% | 117,6 k € | +0.6% | 116,9 k € | +5.0% | 111,4 k € | -58.5% | 268,7 k € | +37.1% | 195,9 k € | +10.2% | 177,8 k € | |
| Cash | 300,9 k € | +132.2% | 129,6 k € | -26.5% | 176,3 k € | — | — | — | — | — | — | — | — | 366,9 € | -73.4% | 1,4 k € | -87.0% | 10,6 k € | ||||||||||
| Debts | 179,6 k € | +40.7% | 127,7 k € | -16.7% | 153,3 k € | +53.1% | 100,1 k € | +83.7% | 54,5 k € | +22.0% | 44,7 k € | -21.2% | 56,7 k € | +67.5% | 33,8 k € | -8.4% | 36,9 k € | -3.2% | 38,1 k € | +28.8% | 29,6 k € | -83.9% | 184,5 k € | +42.9% | 129,1 k € | -9.5% | 142,7 k € | |
| Staff | 1,5 | 2 | 1 | 2 | 0,9 | 1 | 1 | 1 | 1 | — | — | 0,9 | 1 | 0,9 | ||||||||||||||
Private limited company · Saint-Josse-ten-Noode · incorporated on 03/02/2011 · 1,5 ETP
Private limited company profitable and well capitalised. Cash position rising (+132.2%).
Acceptable counterparty for a moderate engagement. Require 2 fiscal years of detailed accounts before any significant exposure. The abridged model hides revenue.
Advanz Pharma Belgium is a Private limited company incorporated in 2011. Its main activity is: Wholesale of pharmaceutical goods. Its registered office is in Saint-Josse-ten-Noode. It employs on average 1,5 ETP workers (FTE).
Key indicators
7-day free trial, no credit card required.
7-day free trial, no credit card required.
7-day free trial, no credit card required.
Source: Belgian Official Gazette